Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.75 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.75 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.75 |
| ▸ | LDHA | P00338 | 1/20 | 0.75 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.75 |
| ▸ | FBP1 | P09467 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.75 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.75 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.75 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.75 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.75 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275138 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL23647917 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29388941 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL20942825 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29496215 | 0.96 | P2RY1 (0.80) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| Adenosine Phosphate SCHEMBL3828789 | 0.90 | P2RY1 (0.92) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL3694223 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 | |
| SCHEMBL25413594 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 | |
| SCHEMBL29796608 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 | |
| SCHEMBL3694227 | 0.90 | ADORA3 (0.76) | ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019719-A1 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2025-01-16 | — | — | US | claimed |
| EP-3387150-B1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-2691118-B1 | PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS | SCHAEFER KONSTANZE (DE) | 2019-05-01 | — | — | EP | claimed |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4577650-A1 | CHEMICAL MODIFICATION OF GUIDE RNAS WITH LOCKED NUCLEIC ACID FOR RNA GUIDED NUCLEASE-MEDIATED GENE EDITING | Life Edit Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12139707-B2 | Stabilized CRISPR complexes | SYNTHEGO CORPORATION (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240299579-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | ORTHOBIO THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240209356-A1 | Systems and Methods for Modulating CRISPR Activity | SYNTHEGO CORPORATION | 2024-06-27 | — | — | US | disclosed |
| US-20240124895-A1 | NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024042489-A1 | CHEMICAL MODIFICATION OF GUIDE RNAS WITH LOCKED NUCLEIC ACID FOR RNA GUIDED NUCLEASE-MEDIATED GENE EDITING | LifeEDIT Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20210163940-A1 | COMPOSITIONS AND METHODS FOR NICKING TARGET DNA SEQUENCES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3280803-B1 | CHEMICALLY MODIFIED GUIDE RNAS FOR CRISPR/CAS-MEDIATED GENE REGULATION | UNIV LELAND STANFORD JUNIOR (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200131539-A1 | CRISPR/CAS 9-MEDIATED INTEGRATION OF POLYNUCLEOTIDES BY SEQUENTIAL HOMOLOGOUS RECOMBINATION OF AAV DONOR VECTORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-04-30 | — | — | US | disclosed |
| US-20190032091-A1 | Nuclease-Mediated Genome Editing of Primary Cells and Enrichment Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180126003-A1 | NEW TARGETS FOR RNA THERAPEUTICS | CureVac SE (DE) | 2018-05-10 | — | — | US | disclosed |
| US-20170298348-A1 | GENOME EDITING OF HUMAN NEURAL STEM CELLS USING NUCLEASES | BRIGHT OCEANS INTEL-TELECOM CO., LTD. (CN) | 2017-10-19 | — | — | US | disclosed |
| US-20140065223-A1 | PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS | Libera-Koerner, Jeanette (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20130149375-A1 | IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2013-06-13 | — | — | US | disclosed |
| US-20110300205-A1 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139707-B2 | Stabilized CRISPR complexes | DCLRE1B, CPSF1, MRE11 | ADORA1 4319/4885DNPH1 2236/4885PRKAB2 1940/4885 |
| US-12584149-B2 | Nuclease-mediated genome editing of primary cells and related kits | ADAR, RNASE1, CPSF6 | ADORA1 1027/4885DNPH1 4229/4885PRKAB2 1475/4885 |
| US-20260069541-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF ACTIVE AGENTS INCLUDING NUCLEIC ACIDS | PHAX, RNMT, PRKCZ | ADORA1 1944/4885DNPH1 4776/4885PRKAB2 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.